Cimaterol reduces beta-adrenergic receptor density in rat skeletal muscles
- PMID: 1374751
- DOI: 10.2527/1992.701115x
Cimaterol reduces beta-adrenergic receptor density in rat skeletal muscles
Abstract
Interactions between the beta-adrenoceptor agonist cimaterol and beta-adrenoceptors on rat skeletal muscle membranes were examined in two studies. In Exp. 1, muscle samples from eight Sprague-Dawley rats (female, approximately 200 g) were used for competition binding and autoradiographic studies using [125I]cyanopindolol (ICYP) as a radioligand. The affinities or dissociation constants for binding (KD values) for cimaterol in plantaris and soleus muscles were .68 and .92 microM, respectively. Muscle areas stained for succinic dehydrogenase had propranolol-resistant ICYP binding sites; cimaterol did not seem to compete for these sites. In Exp. 2, 60 Sprague-Dawley rats (female, approximately 218 g) were fed 0 or 10 ppm of cimaterol in rat diet that was ground. Groups were killed after 1, 3, 7, 14, or 28 d of treatment. Cimaterol increased BW gain up to 14 d after commencement of treatment, with little or no improvement thereafter. Enhanced weight gain in skeletal muscles also occurred up to 14 d of cimaterol treatment. Densities of beta-adrenoceptors in plantaris and soleus muscle membrane homogenates were estimated using a radioligand binding assay with ICYP. A significant reduction in the number of binding sites (Bmax) was observed after 3 d of cimaterol treatment in plantaris muscle without a change in the KD of ICYP binding. The percentage reductions in Bmax were 26.8, 42.2, 37.7, and 37.8% at 3, 7, 14, and 28 d after cimaterol administration, respectively. In the soleus muscle, significant reductions (44.1 and 29.8%) in Bmax were observed after 3 and 14 d of cimaterol treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles.Biochem Pharmacol. 1991 Oct 9;42(9):1783-9. doi: 10.1016/0006-2952(91)90516-8. Biochem Pharmacol. 1991. PMID: 1681810
-
Ligand binding properties of putative beta 3-adrenoceptors compared in brown adipose tissue and in skeletal muscle membranes.Br J Pharmacol. 1993 Aug;109(4):1157-63. doi: 10.1111/j.1476-5381.1993.tb13743.x. Br J Pharmacol. 1993. PMID: 8104645 Free PMC article.
-
The effects of beta agonists on muscle cells in culture.Domest Anim Endocrinol. 1990 Oct;7(4):477-84. doi: 10.1016/0739-7240(90)90005-k. Domest Anim Endocrinol. 1990. PMID: 1979765
-
Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.Br J Pharmacol. 1993 Jun;109(2):344-52. doi: 10.1111/j.1476-5381.1993.tb13576.x. Br J Pharmacol. 1993. PMID: 8102926 Free PMC article.
-
Beta-adrenergic agonists and hypertrophy of skeletal muscles.Life Sci. 1992;50(6):397-407. doi: 10.1016/0024-3205(92)90374-x. Life Sci. 1992. PMID: 1346465 Review.
Cited by
-
Effect of serum from chickens treated with clenbuterol on myosin accumulation, beta-adrenergic receptor population, and cyclic AMP synthesis in embryonic chicken skeletal muscle cell cultures.In Vitro Cell Dev Biol Anim. 2002 Feb;38(2):102-10. doi: 10.1290/1071-2690(2002)038<0102:EOSFCT>2.0.CO;2. In Vitro Cell Dev Biol Anim. 2002. PMID: 11928992
-
Chronic clenbuterol treatment compromises force production without directly altering skeletal muscle contractile machinery.J Physiol. 2015 Apr 15;593(8):2071-84. doi: 10.1113/jphysiol.2014.287060. Epub 2015 Feb 27. J Physiol. 2015. PMID: 25656230 Free PMC article.
-
Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Br J Pharmacol. 2006 Mar;147(6):587-95. doi: 10.1038/sj.bjp.0706669. Br J Pharmacol. 2006. PMID: 16432501 Free PMC article.
-
Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.Br J Pharmacol. 2006 Mar;147(6):583-6. doi: 10.1038/sj.bjp.0706670. Br J Pharmacol. 2006. PMID: 16432500 Free PMC article.
-
Change of skeletal muscle mass in patients with pheochromocytoma.J Bone Miner Metab. 2019 Jul;37(4):694-702. doi: 10.1007/s00774-018-0959-3. Epub 2018 Sep 20. J Bone Miner Metab. 2019. PMID: 30238430 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources